Denials, Downgrades, and the Mid-Revenue Cycle

How payer scrutiny increases administrative burden, suppresses reimbursement, and reshapes the mid-revenue cycle

ACCUITY

(646) 568-2801 Accuityhealthcare.com info@accuityhealthcare.com

Executive Summary

Over the past several years, payer scrutiny has intensified in ways that few health systems anticipated. What once showed up primarily as isolated denials has evolved into a broader pattern of clinical validation reviews, DRG downgrades, and retrospective reinterpretation of care. For many organizations, the financial impact is clear. Less visible, but equally consequential, is the operational burden these activities place on clinical, revenue, and leadership teams.

Denials and downgrades are often discussed as revenue cycle issues. In practice, they are symptoms of a deeper challenge: how clinical reality is translated into documentation, coding, and ultimately reimbursement. As payer criteria grow more complex and less transparent, even well-run organizations find themselves spending increasing time and effort defending care that was appropriate, necessary, and well delivered.

What makes this moment different is not just the volume of payer scrutiny, but where it concentrates. The mid-revenue cycle has become the focal point where clinical judgment, coding interpretation, and compliance expectations intersect.

When alignment breaks down at this stage, the result is not only lost reimbursement, but administrative rework, extended accounts receivable, and repeated escalation to senior clinical and operational leaders.

This white paper was developed to examine that reality in practical terms. It looks beyond individual denials to explore the mechanics of DRG downgrades, the administrative cost per case, and the cumulative impact of invisible revenue loss that often goes unmeasured. It also examines why reactive workflows struggle to keep pace and what characteristics distinguish models that are able to prevent loss earlier and more consistently.

The goal is not to assign blame or promote a single solution. It is to provide clarity. As reimbursement tightens and scrutiny increases, accuracy, defensibility, and trust in clinical–coding translation matter more than ever. Understanding how and where revenue is lost is the first step toward protecting it.

I hope this analysis proves useful as you assess your own organization's exposure, processes, and priorities in the face of ongoing payer scrutiny.

Jennifer Miecznikoski,
Vice President, Revenue Cycle Operations,
Accuity

The New Reality of Payer Scrutiny

Payer scrutiny has shifted from isolated denials into a broader system of post-care enforcement that reshapes reimbursement well beyond the appeals process.

Today, payer review activity commonly includes:

- Clinical validation programs that reassess severity and medical necessity
- DRG downgrades proposed after discharge
- Retrospective reinterpretation of high-acuity diagnoses
- Partial payments that reduce reimbursement without triggering a formal denial

For hospitals, this change has expanded both the scope and complexity of revenue risk. Financial exposure is no longer limited to claims that are formally denied. Now it includes cases that are paid at a lower DRG or reduced relative weight, often without a clear escalation path.

This pattern is especially pronounced in inpatient populations and among Medicare Advantage plans. High-risk clinical conditions such as sepsis and respiratory failure are frequently reviewed using payer-defined criteria that differ from bedside practice. Even when documentation is thorough, missing or ambiguous clinical signals can result in downgraded payment.

Importantly, many of these actions never reach the appeals stage. DRG downgrades and partial payments frequently bypass formal denial workflows, shifting financial impact earlier in the revenue cycle and changing how loss accumulates.

From an operational standpoint, payer scrutiny now reaches deeper into hospital workflows:

- Coding and CDI teams are pulled into repeated rework
- Revenue integrity staff manage extended review cycles
- Physician advisors are engaged earlier and more often
- Senior leaders are drawn into low-yield escalations

Managing denials in this environment demands more than an effective appeals process. It requires understanding how payer behavior, clinical documentation, and coding interpretation interact across the revenue cycle—and where intervention can prevent loss before it becomes final.

Visible vs. Invisible Loss in the Mid-Revenue Cycle

While hospitals closely track formal denials, a significant portion of financial impact occurs earlier and more quietly, often without triggering an appeal.

Understanding the difference between visible and invisible loss is essential to understanding why denials persist and why traditional response strategies fall short.

Two Types of Revenue Loss

Visible loss

Visible loss – formal claim denials: insurers of qualified health plans on HealthCare.gov deny roughly 19% of hospital claims, each costing an average of $118 to rework. These losses are tangible, logged, and fought through appeals.

Invisible loss

Invisible loss – Revenue lost through DRG downgrades, partial payments, or conservative coding decisions that reduce reimbursement without generating a denial.

Invisible loss: DRG downgrades and partial payment

Invisible loss occurs when reimbursement is reduced without a formal denial. These outcomes often result from payer reinterpretation of clinical severity after discharge, particularly for high-acuity inpatient cases.

Common examples include:

- DRG downgrades proposed during review periods
- Partial payments tied to severity-of-illness disputes
- Shortened lengths of stay that reduce relative weight
- Conservative coding decisions made to avoid downstream denials

In many cases, these downgrades occur during a pre-denial discussion period, when payment has not yet been finalized and opportunities for clinical clarification still exist. Once a downgrade is finalized, it effectively becomes a denial, with immediate financial impact, tighter appeal timelines, and lower likelihood of recovery.

Because the administrative effort required to challenge finalized downgrades often outweighs the expected recovery, many of these outcomes are accepted as final. Over time, they accumulate into a substantial and often underreported margin gap.

Visible vs. Invisible Loss

Dimension	Typical Effort	Invisible Loss (Downgrades & Partial Payment)
Trigger	Formal denial notice	Post-discharge payer review
Visibility	High	Low
Appeal	Defined	Often informal or absent
Administrative	Concentrated	Diffuse and repeated
Financial impact	Tracked	Often undermeasured

Where the losses originate

Both visible and invisible loss trace back to the mid-revenue cycle: where clinical documentation, coding interpretation, and payer criteria must align to accurately reflect care delivered.

When that alignment breaks down:

- Denials become more likely
- DRG downgrades progress without challenge
- Partial payments are accepted as final
- Administrative effort increases while recovery decreases

This dynamic explains why organizations can reduce appeal volumes but still experience declining reimbursement accuracy.

To address both visible and invisible loss, hospitals must first understand the operational and administrative cost created when payer scrutiny is addressed too late in the revenue cycle.

The Administrative Burden of Reactive Denial and Downgrade Workflows

Revenue loss from denials and DRG downgrades is often measured in dollars. Far less visible is the administrative effort required to manage those outcomes once they occur. For many hospitals, the operational cost of responding to payer scrutiny rivals or exceeds the reimbursement at risk.

Denials and downgrades are not single events.

They are workflows that touch multiple teams, repeatedly, over time.

When a DRG downgrade is proposed or finalized, it triggers a sequence of handoffs across the organization

- Initial review by denials or revenue integrity staff
- Coding reassignment and DRG analysis
- Documentation review and clinical validation
- Physician advisor preparation or peer-to-peer engagement
- Tracking, follow-up, and potential appeal submission

Each step adds time, coordination, and delay. The cumulative effect is significant, even when the financial value of the individual case is modest.

Estimated Administrative Effort per Downgraded Case

Activity	Typical Effort
Denials / appeals specialist review	1.5–2.0 hours
Coding reassignment and analysis	1.0–1.5 hours
Revenue integrity coordination	1.0–2.0 hours
Physician advisor or peer review prep	0.5–1.0 hours
Total administrative effort	**4–6.5 FTE hours per case**

Why Reactive Denial and Downgrade Workflows Don’t Scale

Most denial management programs are built to respond after payer action has already occurred. Appeals can recover revenue, but they do so at increasing operational cost. Each case sets off a chain of activity that repeats across teams and over time.

Reactive workflows typically involve:

- Multiple handoffs across CDI, coding, revenue integrity, and appeals teams
- Duplicated chart review and documentation rework
- Escalation to physician advisors and senior clinical leaders for low-yield cases
- Extended accounts receivable and delayed resolution

Over time, labor scales predictably while recovery does not. Each additional dollar recovered requires more effort than the last, creating a diminishing-return cycle that is difficult to sustain.

From a leadership perspective, the impact extends beyond denial volume. As reactive work expands, highly skilled clinical, coding, and revenue leaders are pulled into repetitive defense instead of prevention. This shift:

- Diverts attention from documentation improvement and upstream risk reduction
- Increases reliance on retrospective physician review
- Reduces capacity for strategic payer analysis and contracting

These operational effects often remain hidden until staffing strain, burnout, or delayed initiatives surface as downstream consequences.

Why the Mid-Revenue Cycle Is the Point of Failure

If reactive denial and downgrade workflows don't scale, where should intervention occur instead? For most hospitals, the answer lies in the mid-revenue cycle, the period between patient discharge and final claim submission.

This is the point where clinical reality often gets lost in translation between the language of medicine and the language of coding. Some common issues:

Documentation is written for care, not reimbursement. Clinicians document to support diagnosis and treatment decisions, not to satisfy downstream payer interpretation. Important clinical signals may be present in the record but not expressed in ways that align with coding or audit criteria.



Clinical and coding interpretation diverge. CDI and coding teams apply regulatory guidance and payer rules to documentation that was never created with those frameworks in mind. Even small ambiguities can change how severity, medical necessity, or principal diagnosis is interpreted.

Payer criteria are applied retrospectively. Many reviews occur weeks or months after discharge, using criteria that may differ from bedside practice. At that point, opportunities for clarification are limited and resolution becomes more resource-intensive.

EHR workflows obscure nuance. Templates, copy-forward documentation, and fragmented note structures can make it difficult to surface the clinical evidence payers expect, even when it exists in the chart.

These vulnerabilities are most visible in high-acuity conditions that drive DRG weight and severity metrics. Sepsis and respiratory failure are common examples, where differences between clinical definitions and payer validation criteria frequently result in downgrades or denials. In these cases, the issue is not the care delivered, but how that care is interpreted after the fact.

When misalignment occurs at this stage, the downstream consequences are predictable. DRG risk is identified too late. Clarifications become defensive rather than preventive. Administrative effort increases while recovery potential declines.

The mid-revenue cycle is therefore not just a processing step. It is the critical control point where accurate interpretation can either preserve reimbursement or allow revenue loss to harden into denials, downgrades, and ongoing administrative burden.

What Effective Early Intervention Looks Like

If the mid-revenue cycle is the point of failure, then effective intervention must occur before payer scrutiny hardens into denials, downgrades, or partial payment. This requires a fundamentally different operating model than traditional denial management, one focused on prevention rather than defense.

1 Risk is identified before billing.	High-risk inpatient cases are evaluated in the post-discharge, pre-bill window, when documentation and coding can still be clarified without triggering formal payer disputes. At this stage, the opportunity is to prevent revenue loss rather than attempt to recover it later.
2 Interpretation takes precedence over volume.	The core challenge is rarely missing documentation. More often, clinical evidence exists in the record but is not clearly translated into codable, defensible determinations. Early intervention focuses on resolving these gray areas while there is still time to act.
3 Clinical–coding interpretation is clinically governed.	Automation can surface risk signals and inconsistencies, but clinical judgment is required to determine how those signals should be applied within coding and compliance frameworks. Models that rely on automation alone struggle with defensibility, while models that rely solely on manual review struggle to scale.
4 Clinical evidence is explicitly mapped and preserved.	Supporting indicators such as labs, treatments, and physician assessments are tied directly to diagnoses and procedures. This creates a clearer record that stands up better to retrospective review and reduces downstream administrative effort.
5 Downstream burden is reduced, not redistributed.	Effective models operate within existing workflows, apply determinations directly in the system of record, and avoid creating additional worklists or real-time demands on client teams. The goal is fewer handoffs and less rework, not earlier escalation.

When these elements are in place, DRG risk is resolved earlier. Administrative effort shifts from repeated defense to targeted prevention, and clinical and financial teams spend less time reacting to payer actions.

Early intervention does not eliminate payer scrutiny. It changes where and how that scrutiny is absorbed, allowing hospitals to retain control over clinical–coding interpretation at the point where it matters most.

Accuity as Proof of a Clinically Governed Model

> **“Sustainable denial prevention starts with aligning clinical, financial, and operational accuracy.”**

The operating model described in the previous section has been implemented at scale across hundreds of hospital and health system environments, producing consistent and measurable results.

Accuity applies this clinically governed approach by combining early identification of DRG risk with multidisciplinary clinical–coding interpretation. The model is designed to preserve clinical reality before payment decisions are finalized, while reducing the administrative burden associated with reactive denial and downgrade workflows. This results in:

1. **Lower final DRG assignment denial rates.** A 1.5% final DRG assignment denial rate on Accuity-reviewed cases—whether or not Accuity changes the DRG—reflects the impact of resolving clinical–coding interpretation issues earlier and creating more defensible records before payer scrutiny occurs.

2. **Higher net revenue lift compared with other solutions.** In head-to-head comparisons across inpatient populations, Accuity consistently outperforms other solutions with a 76% higher net revenue lift per 10,000 discharges. This difference reflects not only recovered reimbursement, but also avoided downgrades and reduced administrative drag.

3. **Material improvement in earned reimbursement.** Organizations using this model typically see $3–$6 million in incremental reimbursement per 10,000 discharges, driven by more accurate representation of severity, complexity, and resource use.

4. **Sustained accuracy without increased audit exposure.** Improvements are achieved by preserving clinical reality in documentation and coding, not by inflating severity or increasing query volume. As a result, organizations see improved Case Mix Index accuracy and CC/MCC capture while maintaining defensibility under payer review.

5. **Reduced downstream administrative burden.** By resolving DRG risk earlier, hospitals experience fewer handoffs, fewer escalations to physician advisors, and lower cost per dollar recovered. Denials that do occur are treated as intelligence, informing trend analysis and future prevention rather than triggering repeated rework.

Together, these results demonstrate that a clinically governed model can change both the financial and operational trajectory of denial and downgrade management. The impact is not limited to recovery. It reshapes how hospitals absorb payer scrutiny, shifting effort upstream and restoring control over clinical–coding interpretation where it matters most.

Closing the Loop: From Scrutiny to Control

Payer scrutiny is no longer an episodic challenge. Denials, downgrades, and retrospective reinterpretation have become structural features of the reimbursement environment. As this paper has shown, the true impact extends beyond lost revenue into administrative burden, operational drag, and diminished confidence in how clinical reality is represented after care is delivered.

For hospital leaders, the implications cut across functions. Finance teams face increasing variability and cost per dollar recovered. Clinical leaders are drawn into retrospective defense of appropriate care. Revenue integrity teams absorb growing workloads long after the opportunity for prevention has passed. In each case, the root issue is timing. By the time payer action occurs, control has already shifted away from the provider.

The analysis shows that sustainable improvement requires earlier intervention in the mid-revenue cycle, before payment decisions harden into denials, downgrades, or partial reimbursement.

Models that preserve clinical reality through accurate clinical–coding interpretation, grounded in defensible evidence, change how payer scrutiny is absorbed. Instead of reacting after the fact, organizations retain control at the point where accuracy still matters.

Accuity was built to operate in that space. Its clinically governed AI model applies early, pre-bill interpretation to preserve clinical reality before reimbursement decisions are finalized. By combining intelligent automation with multidisciplinary clinical–coding expertise, Accuity helps hospitals reduce downstream administrative burden, improve reimbursement accuracy, and maintain confidence in the integrity of their records.

As payer scrutiny continues to intensify, the organizations best positioned to respond will not be those that appeal faster, but those that prevent loss earlier. Control, accuracy, and defensibility are no longer optional. They are foundational.

About Accuity

Accuity is an AI-driven clinical intelligence and revenue integrity partner that helps hospitals capture the full value of the care they deliver.

Combining proprietary Amplifi AI technology with a physician-led, multidisciplinary clinical–coding team, Accuity reviews every inpatient chart before billing to identify documentation gaps and clinically driven coding opportunities, ensuring each record is accurate, compliant, and a complete reflection of the care delivered.

The company's proven, AI-first approach delivers an average of $3–$6 million per 10,000 discharges, improves patient acuity metrics such as Case Mix Index accuracy, CC/MCC capture, and Severity of Illness/Risk of Mortality, and builds lasting confidence in clinical and financial performance.

For more information, visit www.accuityhealthcare.com